Risk for adverse events among patients receiving intravenous histamine2-receptor antagonists.
OBJECTIVE
To identify risk factors for adverse drug reactions (ADRs) in patients receiving intravenous histamine2-receptor antagonists (H2-RAs).


METHODS
The study hypothesis was evaluated by performing a logistic regression procedure with a backward elimination of the explanatory variables associated with ADRs.


METHODS
ADRs temporally associated with the use of intravenous H2-RAs served as the dependent variable. Background information about the patients and drug use evaluation criteria in three general areas were entered into the regression analysis.


METHODS
Hospitals were selected from the southeastern US, based on their willingness to participate and their characteristics. Participating hospitals exhibited a variety of sizes and ownership arrangements.


METHODS
1200 adult patients who were receiving intravenous H2-RAs.


RESULTS
Seven percent of patients experienced a presumed ADR (PADR) to intravenous H2-RAs. The only risk factor for ranitidine was for patients who did not have their dosage corrected for renal function ("overdose"); these patients were twice as likely to experience a PADR compared with patients who received the correct dosage as determined by their renal function. Two risk factors for cimetidine were identified: (1) patients taking cimetidine with another medication known to cause a drug interaction; and (2) patient age. No risk factors were identified for famotidine.


CONCLUSIONS
The two risk factors for ADRs identified in this study are preventable. Healthcare providers should strive to prevent ADRs by adjusting patients' dosages based on their renal function and by monitoring patients receiving cimetidine with another medication known to interact with cimetidine.
Ben-Joseph
R
R
Department of Pharmacy Health Care Administration, Shands Hospital, Gainesville, FL.
Segal
R
R
Russell
W L
WL
D000367:Age Factors; D002927:Cimetidine / Q000008:administration & dosage / Q000009:adverse effects*; D004347:Drug Interactions; D015738:Famotidine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D011899:Ranitidine / Q000008:administration & dosage / Q000009:adverse effects*; D012044:Regression Analysis; D012307:Risk Factors
D015738:Famotidine; D002927:Cimetidine; D011899:Ranitidine